Joseph Antonios

Dr. Joseph Antonios

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMercy H. Mazurek
Mercy H. Mazurek
BCBradley A. Cahn
Bradley A. Cahn
MYMatthew M. Yuen
Matthew M. Yuen
APAnjali M. Prabhat
Anjali M. Prabhat
ICIsha R. Chavva
Isha R. Chavva
KSKevin N Sheth
Kevin N Sheth
Radiological examination of the brain is a critical determinant of stroke care pathways. Accessible neuroimaging is essential to detect the presence of intracerebral hemorrhage (ICH). Conventional magnetic resonance imaging (MRI) operates at high magnetic field strength (1.5–3 T), which requires an access-controlled environment, rendering MRI often inaccessible. We demonstrate the use of a low-field MRI (0.064 T) for ICH evaluation. Patients were imaged using conventional neuroimaging (non-contrast computerized tomography (CT) or 1.5/3 T MRI) and portable MRI (pMRI) at Yale New Haven Hospital from July 2018 to November 2020. Two board-certified neuroradiologists evaluated a total of 144 pMRI examinations (56 ICH, 48 acute ischemic stroke, 40 healthy controls) and one ICH imaging core lab researcher reviewed the cases of disagreement. Raters correctly detected ICH in 45 of 56 cases (80.4% sensitivity, 95%CI: [0.68–0.90]). Blood-negative cases were correctly identified in 85 of 88 cases (96.6% specificity, 95%CI: [0.90–0.99]). Manually segmented hematoma volumes and ABC/2 estimated volumes on pMRI correlate with conventional imaging volumes (ICC = 0.955, p = 1.69e-30 and ICC = 0.875, p = 1.66e-8, respectively). Hematoma volumes measured on pMRI correlate with NIH stroke scale (NIHSS) and clinical outcome (mRS) at discharge for manual and ABC/2 volumes. Low-field pMRI may be useful in bringing advanced MRI technology to resource-limited settings.

8 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RERichard G. Everson
Richard G. Everson
WHWilly Hugo
Willy Hugo
LSLu Sun
Lu Sun
JAJoseph Antonios
Joseph Antonios
ALAlexander Lee
Alexander Lee
RPRobert M. Prins
Robert M. Prins
In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and delayed disease progression. These findings suggest that combining ATL-DC with poly-ICLC can induce a polarized interferon response in circulating monocytes and CD8+ T cells, which may represent an important blood biomarker for immunotherapy in this patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01204684.

12 August 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AKAndrew B. Koo
Andrew B. Koo
AEAladine A. Elsamadicy
Aladine A. Elsamadicy
DRDaniela Renedo
Daniela Renedo
MSMargot Sarkozy
Margot Sarkozy
BRBenjamin C. Reeves
Benjamin C. Reeves
CMCharles C Matouk, MD
Charles C Matouk, MD

3 February 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
DRDaniela Renedo
Daniela Renedo
JAJulián N. Acosta
Julián N. Acosta
Nanthiya SujijantaratNanthiya Sujijantarat
Nanthiya Sujijantarat
JAJoseph Antonios
Joseph Antonios
AKAndrew B. Koo
Andrew B. Koo
GFGuido J. Falcone
Guido J. Falcone

2 September 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
DRDaniela Renedo
Daniela Renedo
TBTanyeri Barak
Tanyeri Barak
JDJonathan DeLong
Jonathan DeLong
JAJulian N. Acosta
Julian N. Acosta
Nanthiya SujijantaratNanthiya Sujijantarat
Nanthiya Sujijantarat
CMCharles C Matouk, MD
Charles C Matouk, MD
Background: Ischemic stroke results in significant morbidity and mortality. By examining gene expression of cells comprising stroke clots, we aim to gain valuable insights into the underlying mechanisms of this disease and identify potential biomarkers of stroke cause. Methods: We employed single‐cell RNA sequencing to analyze 10 clot samples from patients diagnosed with large vessel occlusion stroke. We aimed to identify and compare the immune cell compositions and gene expression profiles between stroke clots (atrial fibrillation vs carotid atherosclerosis). We also used Multi‐marker Analysis of Genomic Annotation and genome‐wide association studies summary statistics from the GIGASTROKE consortium to assess associations between genetic variants and cell type‐specific gene expression within the stroke subtypes. Results: Our analysis revealed distinct immune cell populations, including monocytes, macrophages, dendritic cells, neutrophils, and T cells in both clot types. Notably, we observed significant differences in gene expression within the mononuclear phagocytic system cells between clots from patients with atrial fibrillation and carotid atherosclerosis. We identified specific genes associated with atherosclerosis and stroke‐related processes, such as CD74, HLA‐DRB1*01, HTRA1, C1Q, CD81 , and CR1 from patients with carotid atherosclerosis. In atrial fibrillation clots, CD8 T cells and natural killer cells show upregulated expression of genes such as GZMH , GZMB , S100A4 , FCGBP2 , HLA‐A , TIMP1 , CLIC1 , and IFITM2 , indicating their involvement in cytotoxic activities and potential tissue damage. The Multi‐marker Analysis of Genomic Annotation approach highlighted significant genetic associations within leukocytes underscoring the potential roles of B cells, T cells, and macrophages in clot pathogenesis. Conclusions: This study illuminates the immune and transcriptomic landscape within clots, offering potential biomarkers and lays the foundation for future research.

2 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJacob Kosyakovsky
Jacob Kosyakovsky
CRChristina P Rossitto
Christina P Rossitto
JAJoseph Antonios
Joseph Antonios
DRDaniela Renedo
Daniela Renedo
CSChristopher J. Stapleton
Christopher J. Stapleton
Nanthiya SujijantaratNanthiya Sujijantarat
Nanthiya Sujijantarat
Acute ischemic stroke (AIS) is one of the leading global causes of mortality and morbidity. Clearer understanding of stroke etiology is a major clinical objective to determine appropriate strategies for secondary stroke prevention. Histological and molecular analysis of clots retrieved during mechanical thrombectomy (MT) in AIS offers a unique opportunity to study clot composition and its relation to stroke etiology. The field of clot composition analysis has undergone substantial growth in recent years, driven in part by the establishment of MT as the standard of care, as well as its expanding indications. Although many features differ between large-artery atherosclerosis (LAA) and cardioembolic (CE) clots, application of these findings to predicting stroke etiology at a clinical level remains challenging. Moreover, a significant number of patients have multiple comorbidities or suffer a cryptogenic subtype. Next-generation techniques such as multiomic sequencing offer a powerful potential to elevate our understanding of clot pathology and provide the level of granularity required for clinical diagnosis and management. Herein, we provide an updated review of the current state of the field by exploring stroke etiologies and their relationship to clot pathology, including classic histologic features as well as more recent, emerging results from proteomic and transcriptomic analyses.